Skip to content
by Legal Desire
8 July 2024

Kirkland Advises Eli Lilly on $3.2 Billion Morphic Acquisition

Advising firms

Deal team

21 lawyers named
LawyerFirmSeniorityPracticeOffice
Keri Schick Norton Lead Kirkland & Ellis Partner corporate Not stated
Sarkis Jebejian Lead Kirkland & Ellis Partner corporate Not stated
Steven Choi Lead Kirkland & Ellis Partner corporate Not stated
Inhae Song Kirkland & Ellis Associate corporate Not stated
Molly Kaleya Kirkland & Ellis Associate corporate Not stated
Victor Simonte Kirkland & Ellis Associate corporate Not stated
Prince Oroke Kirkland & Ellis Associate corporate Not stated
Sophia Hudson Kirkland & Ellis Partner capital markets Not stated
Sharon Freiman Kirkland & Ellis Partner capital markets Not stated
Lia-Michelle Keane Kirkland & Ellis Associate capital markets Not stated
Soo Kyung Chae Kirkland & Ellis Associate capital markets Not stated
Ryan Paulish Kirkland & Ellis Associate capital markets Not stated
Andrea Murino Kirkland & Ellis Partner antitrust & competition Not stated
Samantha Morelli Kirkland & Ellis Partner antitrust & competition Not stated
Shellie Freedman Kirkland & Ellis Partner technology & IP transactions Not stated
Ben Kovach Kirkland & Ellis Associate technology & IP transactions Not stated
Andy White Kirkland & Ellis Associate technology & IP transactions Not stated
Rob Fowler Kirkland & Ellis Partner executive compensation Not stated
Annemarie Mierzejewski Kirkland & Ellis Associate executive compensation Not stated
Diana Soriano Kirkland & Ellis Associate executive compensation Not stated
Kate Hardey Kirkland & Ellis Partner healthcare Not stated

Stated terms

Stated value
USD 3.20bn ($3.2 billion)
What the figure measures
Total transaction value
Client
Eli Lilly and CompanyBuy-side
Counterparties
Morphic Holding, Inc. (Sell-side)